BiotechTube
Amber Bio

Amber Bio

San Francisco, United States· Est.
amber.bio
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Amber Bio is an early-stage biotech startup developing a novel RNA editing platform designed to perform large, multi-kilobase edits. The company's technology aims to overcome the limitations of current mutation-specific gene therapies by creating a single therapeutic product capable of addressing thousands of different mutations within a disease population. Founded in 2022 and based in San Francisco, the company is backed by a $26 million seed round from investors including Playground Global and Andreessen Horowitz (a16z). Amber Bio is in the pre-clinical platform development stage, building its team and technology with a focus on creating a new paradigm for scalable genetic medicine.

CRISPRGene Therapy

Technology Platform

A first-of-its-kind RNA writing platform designed to perform safe, reversible, multi-kilobase edits, capable of addressing thousands of diverse mutations across a patient population with a single therapeutic product.

Opportunities

The platform's ability to target thousands of mutations with a single product could revolutionize treatment for genetically heterogeneous diseases, aggregating small patient populations into commercially viable markets.
The focus on reversible RNA editing may offer a favorable safety profile that accelerates regulatory acceptance and patient adoption compared to permanent DNA edits.

Risk Factors

The core technology of efficient and specific multi-kilobase RNA editing is novel and faces significant technical and delivery hurdles that must be proven.
The company operates in an intensely competitive gene editing landscape with risk of technological obsolescence.
As a pre-clinical, pre-revenue startup, it is dependent on future financing and successful platform validation.

Competitive Landscape

Amber Bio competes in the broad gene editing space against DNA-editing leaders (e.g., CRISPR Therapeutics, Editas Medicine) and RNA-editing specialists (e.g., Beam Therapeutics, Korro Bio). Its key differentiator is the focus on large-scale, multi-kilobase RNA edits for generalizability, a niche also being explored by companies like Ascidian Therapeutics. Success hinges on demonstrating superior capabilities in scale, precision, and delivery.

More companies in Biologics / Biosimilars →More companies in United States →